Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers

Clinical Cancer Research

Volumn 16, Issue 11, 2010, Pages 3067-3077

  Harrington, Kevin J ^a,b   Karapanagiotou, Eleni M ^a,b   Roulstone, Victoria ^a   Twigger, Katie R ^a   White, Christine L ^a   Vidal, Laura ^a,b   Beirne, Debbie ^c   Prestwich, Robin ^c   Newbold, Kate ^b   Ahmed, Merina ^b   Thway, Khin ^b   Nutting, Christopher M ^a,b   Coffey, Matt ^d   Harris, Dean ^b   Vile, Richard G ^e   Pandha, Hardev S ^f   DeBono, Johann S ^a,b   Melcher, Alan A ^c  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c UNIVERSITY OF LEEDS   (United Kingdom)

^d ONCOLYTICS BIOTECH INC   (Canada)

^e MAYO CLINIC   (United States)

^f UNIVERSITY OF SURREY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOLYTIC REOVIRUS 3; ONCOLYTIC VIRUS; REOLYSIN; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RADIOTHERAPY; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG DOSE ESCALATION; DRUG POTENTIATION; DRUG SAFETY; DRUG TISSUE LEVEL; ERYTHEMA; FATIGUE; FEASIBILITY STUDY; FEVER; FLU LIKE SYNDROME; HEADACHE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFECTION; INJECTION SITE PAIN; LYMPHOCYTOPENIA; MAMMALIAN ORTHOREOVIRUS; NAUSEA; NEUTROPENIA; NONHUMAN; PALLIATIVE THERAPY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; RASH; VIRUS REPLICATION; VIRUS SHEDDING; VOMITING;

ADULT; AGED; ANTIBODIES, VIRAL; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MALE; MAMMALIAN ORTHOREOVIRUS 3; MIDDLE AGED; NEOPLASMS; ONCOLYTIC VIROTHERAPY; RADIOTHERAPY DOSAGE; TISSUE DISTRIBUTION; VIRUS REPLICATION; VIRUS SHEDDING;

EID: 77953093863     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-0054     Document Type: Article

References (25)

1. Harrington KJ, Nutting CM. Interactions between ionizing radiation and drugs in head and neck cancer: How can we maximize the therapeutic index? Curr Opin Investig Drugs 2002;3:807-811
2. Zaidi SH, Huddart RA, Harrington KJ. Novel targeted radiosensitisers in cancer treatment. Curr Drug Discov Technol 2009;6:103-134
3. Rosen L, Evans HE, Spickard A. Reovirus infections in human volunteers. Am J Hyg 1963;77:29-37.
4. Tai JH, Williams JV, Edwards KM, Wright PF, Crowe JE, Jr., Dermody TS. Prevalence of reovirus-specific antibodies in young children in Nashville, Tennessee. J Infect Dis 2005;191:1221-1224 (Pubitemid 40503648)
5. Errington F, Steele L, Prestwich R, et al. Reovirus activates human dendritic cells to promote innate antitumor immunity. J Immunol 2008;180:6018-6026
6. Prestwich RJ, Errington F, Ilett EJ, et al. Tumor infection by oncolytic reovirus primes adaptive antitumor immunity. Clin Cancer Res 2008; 14:7358-7366
7. Aghi M, Martuza RL. Oncolytic viral therapies-the clinical experience. Oncogene 2005;24:7802-7816 (Pubitemid 41670681)
8. Vidal L, Yap T, White CL, et al. Reovirus and other oncolytic viruses for the targeted treatment of cancer. Targ Oncol 2006;1:130-150 (Pubitemid 44566155)
9. Harrington KJ, Melcher A, Vassaux G, Pandha HS, Vile RG. Exploiting synergies between radiation and oncolytic viruses. Curr Opin Mol Ther 2008;10:362-370
10. Hingorani M, White CL, Agrawal VK, Vidal L, Melcher A, Harrington K. Combining radiation and cancer gene therapy: a potential marriage of physical and biological targeting? Curr Cancer Drug Targets 2007; 7:389-409.
11. McKenna WG, Muschel RJ, Gupta AK, Hahn SM, Bernhard EJ. The RAS signal transduction pathway and its role in radiation sensitivity. Oncogene 2003;22:5866-5875 (Pubitemid 37176707)
12. Gupta AK, McKenna WG, Weber CN, et al. Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction. Clin Cancer Res 2002;8:885-892
13. Gupta AK, Cerniglia GJ, Mick R, et al. Radiation sensitization of human cancer cells in vivo by inhibiting the activity of PI3K using LY294002. Int J Radiat Oncol Biol Phys 2003;56:846-853 (Pubitemid 36677381)
14. Liang K, Ang KK, Milas L, Hunter N, Fan Z. The epidermal growth factor receptor mediates radioresistance. Int J Radiat Oncol Biol Phys 2003;57:246-254 (Pubitemid 36959763)
15. Bernhard EJ, Kao G, Cox AD, et al. The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts. Cancer Res 1996;56:1727-1730 (Pubitemid 26119651)
16. Russell JS, Lang FF, Huet T, et al. Radiosensitization of human tumor cell lines induced by the adenovirus-mediated expression of an anti-Ras single-chain antibody fragment. Cancer Res 1999;59: 5239-5244 (Pubitemid 29503988)
17. Twigger K, Vidal L, White CL, et al. Enhanced in vitro and in vivo cytotoxicity of combined reovirus and radiotherapy. Clin Cancer Res 2008;14:912-923 (Pubitemid 351231176)
18. Vidal L, Pandha HS, Yap TA, et al. A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer. Clin Cancer Res 2008;14:7127-7137
19. Forsyth P, Roldán G, George D, et al. A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas. Mol Ther 2008;16:627-632 (Pubitemid 351315004)
20. Yang WQ, Lun X, Palmer CA, et al. Efficacy and safety evaluation of human reovirus type 3 in immunocompetent animals: racine and nonhuman primates. Clin Cancer Res 2004;10:8561-8576 (Pubitemid 40063587)
21. White CL, Twigger KR, Vidal L, et al. Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial. Gene Ther 2008;15:911-920 (Pubitemid 351791478)
22. Qiao J, Wang H, Kottke T, et al. Cyclophosphamide facilitates anti-tumor efficacy against subcutaneous tumors following intravenous delivery of reovirus. Clin Cancer Res 2008;14:259-269 (Pubitemid 351378003)
23. Errington F, White CL, Twigger KR, et al. Inflammatory tumor cell killing by oncolytic reovirus for the treatment of melanoma. Gene Ther 2008;15:1257-1270
24. Prestwich RJ, Ilett EJ, Errington F, et al. Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication. Clin Cancer Res 2009;15:4374-4381
25. Prestwich RJ, Errington F, Steele LP, et al. Reciprocal human dendritic cellnatural killer cell interactions induce antitumor activity following tumor cell infection by oncolytic reovirus. J Immunol 2009; 183:4312-4321